1 min read
Add as a preferred source on GoogleMerck Says Efinopegdutide Meets Phase 2b MASH Trial Goal
The MK-6024-013 trial evaluated once-weekly subcutaneous efinopegdutide at 4 mg, 7 mg and 10 mg in adults with MASH and stage F2 or F3 liver fibrosis.
Merck's efinopegdutide met the primary endpoint in a Phase 2b trial of adults with metabolic dysfunction-associated steatohepatitis (MASH) and stage F2 or F3 liver fibrosis.
Merck announced the result Nov. 9 in the MK-6024-013 trial, which tested once-weekly subcutaneous injections at 4 mg, 7 mg and 10 mg.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.